Jennifer L Peek1,2, Matthew H Wilson2,3,4,5. 1. Medical Scientist Training Program, Vanderbilt University School of Medicine. 2. Department of Cell and Developmental Biology, Vanderbilt University. 3. Department of Pharmacology Vanderbilt University. 4. Department of Medicine, Division of Nephrology and Hypertension, Vanderbilt University Medical Center. 5. Department of Veterans Affairs, Tennessee Valley Health Services, Nashville, Tennessee, USA.
Abstract
PURPOSE OF REVIEW: The aim of this study was to summarize recent findings in kidney gene therapy while proposing cystinuria as a model kidney disease target for genome engineering therapeutics. RECENT FINDINGS: Despite the advances of gene therapy for treating diseases of other organs, the kidney lags behind. Kidney-targeted gene delivery remains an obstacle to gene therapy of kidney disease. Nanoparticle and adeno-associated viral vector technologies offer emerging hope for kidney gene therapy. Cystinuria represents a model potential target for kidney gene therapy due to its known genetic and molecular basis, targetability, and capacity for phenotypic rescue. SUMMARY: Although gene therapy for kidney disease remains a major challenge, new and evolving technologies may actualize treatment for cystinuria and other kidney diseases.
PURPOSE OF REVIEW: The aim of this study was to summarize recent findings in kidney gene therapy while proposing cystinuria as a model kidney disease target for genome engineering therapeutics. RECENT FINDINGS: Despite the advances of gene therapy for treating diseases of other organs, the kidney lags behind. Kidney-targeted gene delivery remains an obstacle to gene therapy of kidney disease. Nanoparticle and adeno-associated viral vector technologies offer emerging hope for kidney gene therapy. Cystinuria represents a model potential target for kidney gene therapy due to its known genetic and molecular basis, targetability, and capacity for phenotypic rescue. SUMMARY: Although gene therapy for kidney disease remains a major challenge, new and evolving technologies may actualize treatment for cystinuria and other kidney diseases.
Authors: Tiffany Zee; Neelanjan Bose; Jarcy Zee; Jennifer N Beck; See Yang; Jaspreet Parihar; Min Yang; Sruthi Damodar; David Hall; Monique N O'Leary; Arvind Ramanathan; Roy R Gerona; David W Killilea; Thomas Chi; Jay Tischfield; Amrik Sahota; Arnold Kahn; Marshall L Stoller; Pankaj Kapahi Journal: Nat Med Date: 2017-02-06 Impact factor: 53.440
Authors: Lauren E Woodard; Richard C Welch; Ruth Ann Veach; Thomas M Beckermann; Feng Sha; Edward J Weinman; Talat Alp Ikizler; Jay A Tischfield; Amrik Sahota; Matthew H Wilson Journal: BMC Nephrol Date: 2019-06-20 Impact factor: 2.388
Authors: Nicole L McIntosh; Geoffrey Y Berguig; Omair A Karim; Christa L Cortesio; Rolando De Angelis; Ayesha A Khan; Daniel Gold; John A Maga; Vikas S Bhat Journal: Sci Rep Date: 2021-02-04 Impact factor: 4.379